Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2018

01-05-2018 | Review Article

Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives

Authors: Philipp Backhaus, Benjamin Noto, Nemanja Avramovic, Lena Sophie Grubert, Sebastian Huss, Martin Bögemann, Lars Stegger, Matthias Weckesser, Michael Schäfers, Kambiz Rahbar

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2018

Login to get access

Abstract

Background

Prostate-specific membrane antigen (PSMA) is the up-and-coming target for molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA expression in physiologic tissue as well as in benign and malignant disease has been reported in various publications. Unlike in prostate cancer, PSMA expression is only rarely observed in non-prostate tumor cells. Instead, expression occurs in endothelial cells of tumor-associated neovasculature, although no endothelial expression is observed under physiologic conditions. The resulting potential for tumor staging in non-prostate malignant tumors has been demonstrated in first patient studies. This review summarizes the first clinical studies and deduces future perspectives in staging, molecular characterization, and PSMA-targeted radionuclide therapy based on histopathologic examinations of PSMA expression.

Conclusions

The non-exclusivity of PSMA in prostate cancer opens a window to utilize the spectrum of available radioactive PSMA ligands for imaging and molecular characterization and maybe even therapy of non-prostate disease.
Literature
1.
2.
3.
4.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.PubMedCrossRef
5.
6.
Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.PubMedCrossRef
7.
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53.PubMedPubMedCentralCrossRef
8.
Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, et al. Preclinical evaluation of [18F]PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med [Internet]. 2016;181768:1–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27789722 .
9.
Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, et al. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84.PubMedPubMedCentralCrossRef
10.
11.
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–88.PubMedCrossRef
12.
Goffin KE, Joniau S, Tenke P, Slawin K, Klein EA, Stambler N, et al. Phase 2 study of 99m Tc-trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic lymph node dissection. J Nucl Med [Internet]. 2017; Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.116.187807 .
13.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;42:197–209.PubMedPubMedCentralCrossRef
14.
15.
Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–68.PubMedPubMedCentralCrossRef
16.
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of 68Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high-risk prostate cancer. J Urol [Internet]. 2016;195:1436–43. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534715053975 .CrossRef
17.
Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging [Internet]. 2016;43:2114–21. Available from: /link?doi=10.1007/s00259-016-3435-0 .CrossRef
18.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.PubMedCrossRef
19.
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med [Internet]. 2015;56:1185–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26112024 .CrossRef
20.
21.
22.
Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30:628–36.PubMedCrossRef
23.
Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J, et al. Evaluation of practical interpretation hurdles in 68Ga-PSMA PET/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin Nucl Med [Internet]. 2017;42:322–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28481787 .CrossRef
24.
25.
Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776–87.PubMedCrossRef
26.
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging [Internet]. 2017:1–20. Available from: http://link.springer.com/10.1007/s00259-017-3780-7 .
27.
Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMed
28.
Crowley MJP, Scognamiglio T, Liu YF, Kleiman DA, Beninato T, Aronova A, et al. Prostate-specific membrane antigen is a potential antiangiogenic target in adrenocortical carcinoma. J Clin Endocrinol Metab. 2016;101:981–7.PubMedCrossRef
29.
Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal adenoma. J Med Imaging Radiat Oncol. 2016;60:514–7.PubMedCrossRef
30.
31.
Sasikumar A, Joy A, Pillai MRA, Alex TM, Narayanan G. 68Ga-PSMA PET/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med. 2017;42:1.CrossRef
32.
33.
34.
Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, et al. Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:195–6.PubMedCrossRef
35.
36.
37.
Derlin T, Weiberg D, Sohns JM. Multitracer molecular imaging of Paget disease targeting bone remodeling, fatty acid metabolism, and PSMA expression on PET/CT. Clin Nucl Med. 2016;41:991–2.PubMedCrossRef
38.
39.
40.
41.
Sasikumar A, Joy A, Pillai MRA, Raman V, Vasudevan A, Madhavan J. A rare case of rectal carcinoma and prostate carcinoma with coexistent Paget’s disease mimicking bone metastases in both 18F-FDG and 68Ga PSMA PET/CT. Eur J Nucl Med Mol Imaging [Internet]. 2017;44:173. Available from: http://link.springer.com/10.1007/s00259-016-3529-8 .CrossRef
42.
43.
44.
45.
46.
Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart JR, Maes A, et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44:689–94.PubMedCrossRef
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
Šácha P, Zámečník J, Bařinka C, Hlouchová K, Vícha A, Mlčochová P, et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience. 2007;144:1361–72.PubMedCrossRef
60.
61.
62.
63.
Haffner MC, Laimer J, Chaux A, Schäfer G, Obrist P, Brunner A, et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol. 2012;25:1079–85.PubMedCrossRef
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
Nadebaum DP, Hofman MS, Mitchell CA, Siva S, Hicks RJ. Oligometastatic renal cell carcinoma with sarcomatoid differentiation demonstrating variable imaging phenotypes on 68Ga-PSMA and 18F–FDG PET/CT: a case report and review of the literature. Clin Genitourin Cancer [Internet]. Elsevier Inc.; 2017;1–5. Available from: https://​doi.​org/​10.​1016/​j.​clgc.​2017.​08.​009.
77.
78.
Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med Springer Japan. 2015;29:877–82.CrossRef
79.
Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68 Ga prostate-specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol [Internet]. 2017;61:372–8. Available from: http://doi.wiley.com/10.1111/1754-9485.12590 .CrossRef
80.
Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging [Internet]. 2017;44:102–7. Available from: /link?doi=10.1007/s00259-016-3360-2 .CrossRef
81.
82.
Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90.PubMedCrossRef
83.
Al-Ahmadie HA, Olgac S, Gregor PD, Tickoo SK, Fine SW, Kondagunta GV, et al. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol. 2008;21:727–32.PubMedCrossRef
84.
85.
86.
Sasikumar A, Joy A, Nanabala R, Pillai MRA, Thomas B, Vikraman KR. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:795–6.PubMedCrossRef
87.
Soydal C, Alkan A, Ozkan E, Demirkazik A, Kucuk N. Ga-68 PSMA accumulation in hepatocellular carcinoma. Clin. Oncol. 2016;1.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
Froehner M, Kuithan F, Zöphel K, Heberling U, Laniado M, Wirth MP. Prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography and immunohistochemical findings in a patient with synchronous metastatic penile and prostate cancer. Urology [Internet]. Elsevier Inc.; 2017;101:e5–6. Available from: http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S009042951630923​2.
101.
102.
103.
Chan M, Schembri GP, Hsiao E. Serous cystadenoma of the pancreas showing uptake on 68Ga PSMA PET/CT. Clin Nucl Med. 2017;42:56–7.PubMedCrossRef
104.
105.
Kanthan GL, Izard MA, Emmett L, Hsiao E, Schembri GP. Schwannoma showing avid uptake on 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med [Internet]. 2016;41:703–4. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27405039.​CrossRef
106.
Rischpler C, Maurer T, Schwaiger M, Eiber M. Intense PSMA-expression using 68Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging. 2016;43:193–4.PubMedCrossRef
107.
108.
109.
110.
111.
112.
113.
114.
de Keizer B, Krijger GC, Ververs FT, van Es RJJ, de Bree R, Willems S. 68Ga-PSMA PET-CT imaging of metastatic adenoid cystic carcinoma. Nucl Med Mol Imaging [Internet]. Nuclear Medicine and Molecular Imaging. 2017;51:360–361. Available from: https://​doi.​org/​10.​1007/​s13139-016-0445-6.
115.
Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging [Internet]. 2017; Available from: http://link.springer.com/10.1007/s00259-017-3737-x .
116.
Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, Wetterauer U, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70:562–9.PubMed
117.
118.
119.
120.
121.
122.
Zacho HD, Nielsen JB, Dettmann K, Hjulskov SHPL. 68Ga-PSMA PET/CT uptake in intramuscular myxoma imitates prostate cancer metastasis. Clin Nucl Med. 2017;42:487–8.
123.
124.
125.
126.
127.
128.
129.
Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3.PubMedCrossRef
130.
131.
132.
133.
Gupta M, Choudhury P, Gupta G, Gandhi J. Metastasis in urothelial carcinoma mimicking prostate cancer metastasis in Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography in a case of synchronous malignancy. Indian J Nucl Med [Internet]. 2016;31:222. Available from: http://www.ijnm.in/text.asp?2016/31/3/222/183615 .CrossRef
134.
135.
136.
137.
138.
139.
140.
Derlin T, Baumann U, Bengel FM. Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma. Eur J Nucl Med Mol Imaging. 2015;42:1943–4.PubMedCrossRef
141.
142.
Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540–7.PubMedCrossRef
143.
144.
Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50:472–83.PubMedCrossRef
145.
Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res [Internet]. 2000;6:4049–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11051255 .
146.
147.
148.
149.
150.
Conway RE, Joiner K, Patterson A, Bourgeois D, Rampp R, Hannah BC, et al. Prostate-specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis. 2013;16:847–60.PubMedCrossRef
151.
Conway RE, Rojas C, Alt J, Nováková Z, Richardson SM, Rodrick TC, et al. Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis. 2016;19:487–500.PubMedCrossRef
152.
153.
154.
O’Connor JPB, Jayson GC. Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res. 2012;18:6588–98.PubMedCrossRef
155.
156.
157.
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175:G1–34.PubMedCrossRef
158.
Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, Sebag F, et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging. 2010;37:1669–78.PubMedCrossRef
159.
160.
161.
Ha D, Bing SJ, Ahn G, Kim J, Cho J, Kim A, et al. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis. FEBS J. 2016;283:3438–56.PubMedCrossRef
162.
163.
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64:52–60.PubMedPubMedCentralCrossRef
164.
Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin [Internet]. 2016;55:123–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27350005 .
165.
166.
Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–88.PubMedPubMedCentralCrossRef
167.
168.
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med [Internet]. 2016;57:1334–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27056618 .CrossRef
169.
Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. Clin Nucl Med [Internet]. 2016;41:522–8. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27088387.
170.
Dash A, Pillai MRA, Knapp FF. Production of 177Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging (2010). 2015;49:85–107.
171.
172.
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22: radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.PubMedPubMedCentralCrossRef
Metadata
Title
Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives
Authors
Philipp Backhaus
Benjamin Noto
Nemanja Avramovic
Lena Sophie Grubert
Sebastian Huss
Martin Bögemann
Lars Stegger
Matthias Weckesser
Michael Schäfers
Kambiz Rahbar
Publication date
01-05-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3922-y

Other articles of this Issue 5/2018

European Journal of Nuclear Medicine and Molecular Imaging 5/2018 Go to the issue

Original Article

Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients

Editorial

Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse

Letter to the Editor

Reply to: “All that glitters is not gold – new reconstruction methods using Deauville criteria for patient reporting”

Guidelines

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer

Original Article

Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population

Image of the Month

Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy